Speaker
Description
Background/Aim
Hepatocellular carcinoma (HCC) is an increasingly common and highly lethal cancer that often develops through the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), steatohepatitis (MASH), and cirrhosis. Physical activity and sleep influence key metabolic and inflammatory pathways along this disease continuum, yet the potential public health impact of improving these behaviours remains unclear. We aim to quantify the associations between physical activity and sleep with liver disease progression and HCC risk, evaluate the causal nature of these relationships, and estimate the potential prevention benefits achievable through realistic behavioural interventions.
Methods
We will analyse data from the UK Biobank (~500,000 participants) and the European Prospective Investigation into Cancer and Nutrition (EPIC; ~520,000 participants). Associations of physical activity and sleep with MASLD, MASH, cirrhosis and HCC will be assessed using multivariable regression models. Causality will be investigated using two-sample and Bayesian graphical Mendelian randomisation analyses. Together with collaborator Duco Mülder from Erasmus University Medical Center, effect estimates will be incorporated into a newly developed MISCAN-Liver microsimulation model to project the impact of population-wide and risk-targeted interventions on liver disease and HCC outcomes. Key outputs will include HCC cases prevented, life-years gained and cost per life-years gained.
Results
No results yet, since the study starts next spring.
Conclusion
This will be the first study to combine lifestyle behaviours, prospective cohort analyses, causal inference and microsimulation to quantify behavioural prevention of HCC. It will introduce the first MISCAN Liver model and the first precision targeted projections for behavioural HCC prevention.